These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37326917)

  • 1. Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule.
    Temrikar ZH; Golden JE; Jonsson CB; Meibohm B
    Clin Pharmacokinet; 2023 Jul; 62(7):943-953. PubMed ID: 37326917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial Dose Selection under the Animal Rule.
    Wu K; Choi SY; Bergman K; Seo S
    Clin Pharmacol Ther; 2021 Apr; 109(4):971-976. PubMed ID: 33565088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing efficacy of human products using animals: the US food and drug administration's "animal rule".
    Snoy PJ
    Vet Pathol; 2010 Sep; 47(5):774-8. PubMed ID: 20551476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule.
    Bergman KL; Krudys K; Seo SK; Florian J
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):153-160. PubMed ID: 28299529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Working with the U.S. Food and Drug Administration to obtain approval of products under the Animal Rule.
    Park GD; Mitchel JT
    Ann N Y Acad Sci; 2016 Jun; 1374(1):10-6. PubMed ID: 27336401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
    Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
    Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-infective agents, biologics, and vaccines approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research in 1993.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):908. PubMed ID: 8031072
    [No Abstract]   [Full Text] [Related]  

  • 10. Extending the US Food and Drug Administration's Postmarket Authorities.
    Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
    JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(105):37988-98. PubMed ID: 12049094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule.
    Bai JPF; Hsu CW
    J Pharm Sci; 2019 Feb; 108(2):798-806. PubMed ID: 30244014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
    Beakes-Read G; Neisser M; Frey P; Guarducci M
    Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.
    Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL
    PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals.
    Hey SP; Kesselheim AS; Patel P; Mehrotra P; Powers JH
    JAMA Intern Med; 2020 Jan; 180(1):131-138. PubMed ID: 31710344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.